Medtronic's Neurostimulator DBS System Receives CE Mark
Zacks Investment Research | Jan 12, 2020 09:40PM ET
Medtronic plc (NYSE:MDT) received the CE Mark for its Percept PC neurostimulator in the European Union (EU) for the treatment of symptoms associated with diseases like Parkinson’s. The Percept PC neurostimulator is the only Deep Brain Stimulation (DBS) system to be launched in the EU with BrainSense technology.
Per Medtronic, the Percept PC with BrainSense technology is a significant improvement as it will provide patients and caregivers with objective patient-specific brain signal data to customize treatment options. The data, which will include recorded data outside of clinic visits, will be based on patients’ neuronal activity.
Notably, the Percept PC neurostimulator will be available in western Europe from Jan 15 and will be launched in additional regions per local regulations. Currently, the neurostimulator is under the FDA’s review.
With the approval, Medtronic aims to globally strengthen its Brain Therapies segment under its Restorative Therapies Group business.
A Peek Into Percept PC
The Percept PC neurostimulator, having an improved battery life compared with Medtronic’s Activa PC neurostimulator, includes various upgraded features like access to improved medical imaging and low pulse width. The most important feature of the neurostimulator is that it includes an Enhanced Patient Programmer, using a user-friendly, custom-configured Samsung (KS:005930) mobile device, allowing patients to easily manage their therapy.
Significance of the Approval
Per the medical fraternity, compared with standard medication, DBS is a proven system to improve motor function in patients with Parkinson’s disease. However, DBS, with the currently available systems, is not enough as physicians have to take therapeutic decisions based mainly on clinical assessments and patient-reported information.
However, the Percept PC neurostimulator along with the BrainSense technology is an advanced DBS that can sense and record brain signals, while delivering therapy to patients with neurologic disorders such as Parkinson’s disease. The technology enables clinicians to track patient-specific brain signals and correlate these with patient-recorded events, which may include symptoms or side-effects allied with their disease or medications to treat it. This enables more tailored, data-driven neurostimulation treatment.
Get The News You Want
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.